Alexion data presented at 2025 AANEM Annual Meeting and MGFA Scientific Session underscores pioneering C5 inhibition leadership in gMG

New data on gefurulimab, a novel dual-binding nanobody, from the PREVAIL Phase III trial will highlight its potential as an effective, self-administered treatment option Robust real-world evidence will reinforce the clinical benefits of Ultomiris and Soliris, including reduced steroid burden Alexion, AstraZeneca Rare Disease, will deliver 18 presentations, including four oral presentations, from its leading rare neurology portfolio at the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and the Myasthenia Gravis Foundation of America (MGFA) Scientific Session in San Francisco, California, 29 October to 1 November 2025. Presentations will feature topline data from the global PREVAIL Phase III trial evaluating gefurulimab in adults with anti-acetylcholine receptor (AChR) antibody-positive (Ab+) generalised myasthenia gravis (gMG), as well as robust real-world data and clinical insights that further reinforce the safety profiles and efficacy of Ultomiris (ravulizumab) and Soliris (eculizumab). Christophe Hotermans, Senior Vice President, Head of Global Medical Affairs, Alexion, said: “At this year’s MGFA Scientific Session, we are proud to reinforce our pioneering leadership in C5 inhibition with topline data from the PREVAIL Phase III trial supporting the potential for gefurulimab to deliver early and sustained disease control to patients with gMG. Alongside this, we will share real-world and clinical evidence further establishing Ultomiris as a differentiated therapeutic option and underscoring the impact of our portfolio in addressing critical unmet needs in gMG treatment, such as reducing steroid burden.” New data on gefurulimab will highlight its potential to provide early and sustained disease control An oral presentation at the MGFA Scientific Session will share topline results from the global PREVAIL Phase III trial evaluating gefurulimab, a dual-binding nanobody optimised for subcutaneous self-administration, in adult patients with AChR-Ab+ gMG. The trial met its primary and all secondary endpoints, with gefurulimab demonstrating a statistically significant and clinically meaningful improvement from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score at week 26 compared to placebo. Two additional posters at the MGFA Scientific Session will provide further insights into the delivery of gefurulimab via prefilled syringe (PFS) and auto injector (AI). Results from a Phase I parallel-group study in healthy adults will show that pharmacokinetic exposure following a single subcutaneous dose of gefurulimab administered via autoinjector (AI) was comparable to administration via prefilled syringe (PFS). Separately, results from a human factors validation study will demonstrate that gefurulimab AI and PFS user interfaces can be used safely and effectively with positive user experiences. Evidence further substantiates the steroid-sparing role of Ultomiris and Soliris Several presentations at the MGFA Scientific Session will explore the real-world impact of corticosteroid use on patients with gMG. An encore oral presentation will highlight a retrospective study of patients with gMG showing that corticosteroid-related toxicity was higher in patients with ≥3 months’ continuous use of corticosteroids versus those with <3 months’ continuous use, or no use at all. Furthermore, a retrospective study of patients with gMG will demonstrate a significant increase in healthcare resource utilisation in patients with high corticosteroid toxicity. Data will also be presented at the AANEM Annual Meeting on the reduced corticosteroid burden following treatment with Ultomiris or Soliris . An encore poster presentation will highlight data from the global MG SPOTLIGHT Registry showing reduced concomitant immunosuppressive therapies and oral corticosteroids burden in patients with AChR-Ab+ gMG treated with Ultomiris in routine clinical practice. Additionally, an encore poster presentation of a retrospective analysis of a United States (US) claims database will demonstrate greater reduction in oral corticosteroid use after 12 months in patients with gMG receiving treatment with Ultomiris or Soliris compared with a neonatal Fc receptor (FcRn) inhibitor. Studies spotlight the effectiveness of meningococcal infection risk mitigation strategies for treatment with Ultomiris and Soliris Two oral presentations at the MGFA Scientific Session will reinforce the effectiveness of Alexion’s meningococcal infection risk mitigation strategies. An analysis of the Alexion safety database will suggest that US Neisseria meningitidis -related risk mitigation strategies are effective in patients receiving Ultomiris or Soliris . Separately, a study of antibiotic prophylaxis (AB-PPx) risk mitigation practices across pivotal trials of Alexion’s C5 inhibitors in adults will demonstrate AB-PPx durations varied at initiation of treatment with Ultomiris or Soliris , with the majority of patients receiving it for either 1-30 days (US) or >1y (ex-US). Penicillin-class AB-PPx was most utilised, regardless of geography. Real-world evidence underscores HCP confidence in Ultomiris and its value across the gMG treatment paradigm At the MGFA Scientific Session, a poster presentation of a retrospective subanalysis of US medical records will show that patients treated with Ultomiris within 2 years of gMG diagnosis trended toward greater improvements in MG-ADL scores, minimal manifestation and MG exacerbation-associated hospitalizations than those receiving efgartigimod, a FcRn inhibitor. A separate poster presentation will highlight real-world evidence showing that patients with gMG who initiated treatment with Ultomiris had a statistically significantly greater reduction in healthcare resource utilisation than patients who started on efgartigimod. Two additional poster presentations will provide real-world insights on the drivers of healthcare provider-initiated switches to Ultomiris in gMG, revealing that transitions were driven by unmet needs and provider confidence in Ultomiris, or limitations of intermittent therapy and inability to meet expectations for improved, sustained disease control. Alexion presentations during the 2025 AANEM Annual Meeting and MGFA Scientific Session Lead Author Abstract Title Presentation Details Gwathmey, K. Efficacy and safety of subcutaneous self-administered gefurulimab in generalized myasthenia gravis (PREVAIL): Topline results from a phase 3, randomized, double-blind, placebo-controlled study MGFA Scientific Session Oral Presentation 29 October 2025 11:30 – 11:39 PST Ragole, T. Longitudinal associations of corticosteroid dose with corticosteroid toxicity in patients with generalized myasthenia gravis in the United States ( Encore ) MGFA Scientific Session Oral Presentation 118 29 October 2025 13:00 – 13:07 PST Akpoji, U. Characterization of antibiotic prophylaxis risk mitigation practices across Alexion complement 5 inhibitor phase III clinical trials MGFA Scientific Session Oral Presentation 99 29 October 2025 13:32 – 13:39 PST Pandya, S. Incidence and outcome of meningococcal infection with eculizumab or ravulizumab in patients with generalized myasthenia gravis or neuromyelitis optica spectrum disorder: an updated analysis of US clinical practice MGFA Scientific Session Oral Presentation 109 29 October 2025 13:40 – 13:47 PST Gwathmey, K. Usability of gefurulimab autoinjector (AI) and Prefilled Syringe (PFS) devices: A human factors (HF) validation study MGFA Scientific Session Poster Presentation 34 29 October 2025 From 14:30 – 15:00 PST McEneny, A. Phase 1 study evaluating gefurulimab pharmacokinetics and safety following delivery via autoinjector or prefilled syringe in healthy adults MGFA Scientific Session Poster Presentation 52 29 October 2025 From 14:30 – 15:00 PST Saccà, F. Assessing efficacy and safety of gefurulimab in generalized myasthenia gravis: baseline characteristics from PREVAIL ( Encore ) MGFA Scientific Session Poster Presentation 74 29 October 2025 From 14:30 – 15:00 PST Scheiner, C. Outcomes for patients receiving ravulizumab or efgartigimod treatment within two years of generalized myasthenia gravis (gMG) diagnosis: A retrospective sub-analysis of US medical records MGFA Scientific Session Poster Presentation 78 29 October 2025 From 14:30 – 15:00 PST Yungher, B. Assessing oral corticosteroid tapering in ravulizumab-treated adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: The phase 4, a global OCTAGON study design MGFA Scientific Session Poster Presentation 92 29 October 2025 From 14:30 – 15:00 PST Ragole, T. Corticosteroid toxicity and related healthcare resource utilization in patients with myasthenia gravis in the USA MGFA Scientific Session Poster Presentation 118 29 October 2025 From 14:30 – 15:00 PST Snook, R. Healthcare resource utilization in early initiators of ravulizumab versus efgartigimod for treatment of generalized myasthenia gravis in the USA MGFA Scientific Session Poster Presentation 12 29 October 2025 From 14:30 – 15:00 PST Bhattacharyya, S. Predictors of myasthenia gravis hospitalizations in the PREDICT Study MGFA Scientific Session Poster Presentation 10 29 October 2025 From 14:30 – 15:00 PST Kutz, C. Retrospective analysis of efgartigimod alfa-fcab or efgartigimod alfa and hyaluronidase-qvfc switches to ravulizumab in patients with Myasthenia Gravis (MG) MGFA Scientific Session Poster Presentation 97 29 October 2025 From 14:30 – 15:00 PST Kutz, C. Retrospective analysis of intravenous immunoglobulin (IVIg) infusion switches to ravulizumab (Ultomiris) in patients with myasthenia gravis (MG) MGFA Scientific Session Poster Presentation 98 29 October 2025 From 14:30 – 15:00 PST Narayanswami, P. Effectiveness and safety of ravulizumab in generalized myasthenia gravis: Updated Registry analyses ( Encore ) AANEM Annual Meeting Poster Presentation 189 Session I: 30 October 2025 from 18:15 – 18:45 PST Session II: 31 October 2025 from 9:30 – 10:00 PST Nowak, R. Concomitant immunosuppressive therapy use with ravulizumab: analysis of a generalized myasthenia gravis global Registry ( Encore ) AANEM Annual Meeting Poster Presentation 190 Session I: 30 October 2025 from 18:15 – 18:45 PST Session II: 31 October 2025 from 9:30 – 10:00 PST Streicher, N. Prediction of myasthenia gravis crisis events by a machine learning algorithm (adaptation) AANEM Annual Meeting Poster Presentation 187 Session I: 30 October 2025 from 18:15 – 18:45 PST Session III: 31 October 2025 from 14:45 – 15:15 PST Silvestri, N. Oral corticosteroid use in US patients with generalized myasthenia gravis (gMG) receiving complement C5 or neonatal Fc receptor inhibitors ( Encore ) AANEM Annual Meeting Poster Presentation 188 Session I: 30 October 2025 from 18:15 – 18:45 PST Session III: 31 October 2025 from 14:45 – 15:15 PST Notes Alexion Alexion, AstraZeneca Rare Disease, is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and delivery of life-changing medicines. A pioneering leader in rare disease for more than three decades, Alexion was the first to translate the complex biology of the complement system into transformative medicines, and today it continues to build a diversified pipeline across disease areas with significant unmet need, using an array of innovative modalities. As part of AstraZeneca, Alexion is continually expanding its global geographic footprint to serve more rare disease patients around the world. It is headquartered in Boston, US. AstraZeneca AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca . Contacts For details on how to contact the Investor Relations Team, please click here . For Media contacts, click here . tags Corporate and financial AstraZeneca Websites This website is intended for people seeking information on AstraZeneca's worldwide business. Our country sites can be located in the AZ Network. Veeva ID: Z4-68564 Date of next review: August 2026 Resources All resources Open Innovation Externally sponsored scientific research Medical Information for HCPs US prescription assistance programmes Global clinical trials information Medicines Report a possible side effect Quick links Media Investor Relations Partnering Careers Sustainability Modern Slavery Statement AZethics – Report A Concern Supplier information Social Media Community Guidelines Social Media Linkedn Instagram Facebook Twitter YouTube Glassdoor utility links Legal notice and Terms of Use Privacy notice Site map Contact us Cookie preferences © AstraZeneca 2026 You are now leaving AstraZeneca.com You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. AstraZeneca provides this link as a service to website visitors. AstraZeneca is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit. Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed. Cancel Continue Important notice for users You are about to access AstraZeneca historic archive material. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data. Please refer to your approved national product label (SmPC) for current product information. I have read this warning and will not be using any of the contained product information for clinical purposes. I disagree I agree

The release as fetched from its publisher. astrazeneca.com ↗